Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals / MedCity
Frank Vinluan / medcitynews - Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly. The post Akt…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, January 10, 2026, 10:21 am / permalink 17733 / 8 stories in 2 months
FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome / Endpoints
Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Monday, January 5, 2026, 1:21 am / permalink 17484 / 2 stories in 2 months
Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer / OncoDaily
oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, January 3, 2026, 11:20 am / permalink 17458 / 7 stories in 2 months
Judge blocks 340B rebate pilot program / Beckers
Ella Jeffries / beckershospitalreview - A federal judge granted a temporary restraining order blocking the Department of Health and Human Services from launching its 340B Rebate Model Pilot Program, which was scheduled to begin Jan. 1, 2026. U.S. District Judge Lance Walker of the District of M…
#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy
Saturday, January 3, 2026, 7:22 am / permalink 17451 / 5 stories in 2 months
Advocates Applaud DEA’s Fourth Extension of Remote Prescribing Flexibilities / MedCity
Marissa Plescia / medcitynews - The DEA extended telemedicine prescribing flexibilities for controlled substances through the end of 2026, drawing praise from telehealth advocates who are urging a permanent solution.The post Advocates Applaud DEA’s Fourth Extension of Remote Prescribing…
#healthcare #pharmaceuticals #publichealth #governmentpolicy
Friday, January 2, 2026, 6:22 pm / permalink 17439 / 9 stories in 2 months
AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer / Endpoints
Ayisha Sharma / endpoints - AstraZeneca is spending $100 million upfront to secure ex-China rights for an early-stage cancer drug developed by Jacobio Pharma. The UK drugmaker will be responsible for advancing and selling the oral pan-KRAS inhibitor, JAB-23E73, in ...
#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment
Saturday, December 27, 2025, 6:20 am / permalink 17306 / 7 stories in 2 months
Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug / Endpoints
Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...
#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #vaccinesafety
Saturday, December 27, 2025, 2:21 am / permalink 17302 / 3 stories in 2 months
Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss / MedCity
Frank Vinluan / medcitynews - Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #drugdevelopment #fda
Tuesday, December 23, 2025, 3:22 pm / permalink 17254 / 36 stories in 2 months
FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer / OncoDaily
oncodaily - On December 17, 2025, the FDA issued a regular approval for rucaparib (Rubraca®), marking the formal conversion of its earlier accelerated authorization into full approval for BRCA-mutated metastatic castration-resistant prostate […]
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Saturday, December 20, 2025, 9:20 pm / permalink 17185 / 13 stories in 2 months
FDA Removes Key Limitation on the Use of Real-World Evidence in Regulatory Reviews / OncoDaily
oncodaily - On December 15, 2025, the U.S. Food and Drug Administration (FDA) announced a significant update to its regulatory approach regarding the use of real-world evidence (RWE) in drug and medical […]
#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda
Saturday, December 20, 2025, 4:21 pm / permalink 17179 / 13 stories in 2 months
Optum Rx: 100% of network community pharmacies shift to cost-based model / Fierce
fiercehealthcare - Earlier this year, Optum Rx announced that it would shift to a cost-based model, which would boost reimbursements for brand-name drugs at community pharmacies.
#healthcare #pharmaceuticals #drugpricing #corporatetakeover
Friday, December 19, 2025, 5:22 am / permalink 17127 / 4 stories in 2 months
Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025 / OncoDaily
oncodaily - Eli Lilly and Company has announced the election of Carolyn R. Bertozzi, Ph.D., as a returning member of its Board of Directors, effective December 8, 2025. In her renewed role, […]
#healthcare #pharmaceuticals #elililly #biotech #drugdevelopment
Monday, December 15, 2025, 4:22 am / permalink 16960 / 2 stories in 3 months
FDA approves 1st gene therapy for Wiskott-Aldrich syndrome / Beckers
Ella Jeffries / beckershospitalreview - The FDA has approved Waskyra (etuvetidigene autotemcel), the first gene therapy for Wiskott-Aldrich syndrome, a rare and life-threatening immune disorder. Waskyra is indicated for pediatric patients 6 months and older, as well as adults with Wiskott-Aldri…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Monday, December 15, 2025, 2:21 am / permalink 16954 / 4 stories in 3 months
Zoliflodacin shows promise as single-dose treatment for gonorrhea
A Phase III trial has demonstrated that zoliflodacin – a single-dose oral antibiotic – is highly effective against drug‐resistant gonorrhea, offering an innovative solution to a mounting public health threat. The encouraging results suggest a potential game‐changer in the fight against antibiotic-resistant infections.
#healthcare #pharmaceuticals #publichealth #drugdevelopment
Saturday, December 13, 2025, 8:21 pm / permalink 16937 / 2 stories in 3 months
Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial / American Association for Cancer Research
Kathleen Medora / aacr - Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 4:21 am / permalink 16917 / 6 stories in 3 months
Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial / Medical Express
medicalxpress - Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment af…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 1:21 am / permalink 16912 / 5 stories in 3 months
Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial / American Association for Cancer Research
Kathleen Medora / aacr - SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine ther…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Wednesday, December 10, 2025, 11:22 am / permalink 16789 / 15 stories in 3 months
CVS Health agrees to pay $37.8M to settle fraud allegations over insulin pens / Fierce
fiercehealthcare - CVS Health agreed to pay $37.76 million to settle allegations that it dispensed too many insulin pens to patients and improperly billed federal healthcare programs for those prescriptions.
#healthcare #pharmaceuticals #drugpricing #publichealth #corporatetakeover
Monday, December 8, 2025, 12:21 am / permalink 16679 / 2 stories in 3 months
Startup Protego Bio Lands $130M for First-in-Class Drug’s Pivotal Test in Rare Plasma Disorder / MedCity
Frank Vinluan / medcitynews - Protego Biopharma’s lead program is a potential treatment for the rare disease light chain amyloidosis. The startup says the novel mechanism of its oral small molecule should have better outcomes than antibodies from AstraZeneca and Prothena that failed t…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, December 6, 2025, 10:21 am / permalink 16661 / 2 stories in 3 months
UK and US agree zero-tariff deal on pharmaceuticals / ABC News
go - Officials say the U.K. has sealed a deal securing a 0% tariff rate for all U.K. medicines exported to the U.S. for at least 3 years, in return for the U.K. spending more on new medicines
#healthcare #pharmaceuticals #drugpricing #governmentpolicy
Monday, December 1, 2025, 1:23 pm / permalink 16444 / 6 stories in 3 months